David Charles Lubner, Director at Braveheart Bio, Inc. (BRVE), bought 55,555 shares at $18.00 ($1000K) on 2026-08-07, disclosed to the SEC on 2026-08-07.
Director David Charles Lubner purchased $999,990 worth of shares at $18.00, representing the largest insider purchase in the company's history. This significant buy signals confidence in the stock's post-IPO performance and potential for continued growth.
The stock is currently trading at $31.82, representing a 10.68% premium to its 52-week low of $28.75 and hitting its 52-week high of $31.82, indicating strong recent momentum following the August 2026 IPO.
1) IPO and Nasdaq Composite Index inclusion on August 11, 2026, which increased institutional visibility. 2) The company filed a large shelf registration to provide flexibility for future capital raises.
The stock is currently trading at its 52-week high of $31.82, leaving limited room for error if the market corrects after the initial IPO enthusiasm fades.
Nothing distinguishes this filing.
| Filing → |
| TTPH | SELL | 2015-08-17 | $408K | — | Filing → |
| TTPH | SELL | 2015-07-15 | $367K | — | Filing → |
| TTPH | SELL | 2015-06-16 | $725K | — | Filing → |